Bridgeway Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bridgeway Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-31,500	Closed	-$139K	–	1490
2018 Q3	$139K	Hold	31,500	–	–	﹤0.01%	1358
2018 Q2	$227K	Hold	31,500	–	–	﹤0.01%	1293
2018 Q1	$162K	Hold	31,500	–	–	﹤0.01%	1289
2017 Q4	$120K	Buy	+31,500	New	+$82K	﹤0.01%	1318

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bridgeway Capital Management's SRNE Position: Q4 2018 in Review

Bridgeway Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 31,500 shares — an estimated $139K sold.

Bridgeway Capital Management first reported a position in SRNE in Q4 2017 and held it in 4 quarters. The position peaked at $227K in Q2 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

Bridgeway Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Bridgeway Capital Management sold 31,500 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $139K.
Bridgeway Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
Bridgeway Capital Management's Sorrento Therapeutics, Inc. position peaked at $227K in Q2 2018.
78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.